Transcript Systemic Anti Cancer Therapy (SACT) Monthly

ciu
Chemotherapy Intelligence Unit
1. Systemic Anti-Cancer Therapy
An introduction to Chemotherapy
and SACT
Chemotherapy Intelligence Unit
4150 Chancellor Court
Oxford Business Park South
Oxford
OX4 2GX
Email: [email protected]
Website: www.chemodataset.nhs.uk
Some History First…
 Cancer chemotherapy has been provided in the NHS for decades;
 In England the chemotherapy spend is approximately £1.6bn, yet there was
no evidence on how it was spent and whether or not there was variability
across the country;
 The National Chemotherapy Advisory Group report published in 2009 stated
that “accurate, timely and complete data collection is now seen as a priority
assisted by e-prescribing systems”.
 In October 2011, a small project team was established to pilot the SACT
dataset concept over a 6-month time period to achieve proof of concept.
 Five pilot sites across England were invited to take part;
 An agreed data extract was agreed;
 A technical, web-based solution, was scoped and developed;
 A final report was published, with clear recommendations and
implementation timescales.
Some History First… (2)
The national collection of all cancer chemotherapy information in the NHS in
England commenced on 1st April 2012. This is in line with the requirements of
the Department of Health’s policy document Improving Outcomes: A Strategy
for Cancer January 2011.
The Systemic Anti-Cancer Therapy (SACT) Information Standard (ISB 1533):
applies to all organisations providing cancer chemotherapy services in or
funded by the NHS in England relates to all cancer patients, both adult AND
paediatric, in acute inpatient, daycase outpatient settings and delivery in the
community;
Covers chemotherapy treatment for all solid and haematological malignancies,
including those in clinical trials.
Two year Implementation Plan
The dedicated helpdesk team in
Oxford worked with individual NHS
providers to support them with their
monthly uploads.
July 2014
March 2013
81% upload
data
May 2012
29%
providers
upload
data
September
’12
52%
providers
uploading
SACT
March 2014
98% upload
data
147/147
providers
uploading
SACT
What is the value of detailed
chemotherapy treatment data?
1. Linking treatments to
outcomes
2. Identifying variations in
treatment
3. Is a balance being struck
between benefits and
side effects?
Allows additional scrutiny of clinical
decisions
Ineffective drug?
or insufficient dose
of effective drug?
All providers now submitting SACT
ciu
Chemotherapy Intelligence Unit
2. The SACT Dataset
Structure and dataset items
Chemotherapy Intelligence Unit
4150 Chancellor Court
Oxford Business Park South
Oxford
OX4 2GX
Email: [email protected]
Website: www.chemodataset.nhs.uk
The SACT Dataset
young : old
age
benefit
- curative treatment
- disease control
- symptom control
stage : performance status : co-morbidity
Clinical
status
Optimal choice of
clinical management
for desired outcome
Regimen
&
delivery
recording regimen and detail correctly is critical
toxicity
- stopped early
- dose modified
- treatment delayed
SACT Data Set
The dataset consists of 43 data items
split into the following 6 sections:
Section 1: Demographics & Consultant
Section 2: Clinical Status
Section 3: Programme & Regimen
Section 4: Cycle
Section 5: Drug Details
Section 6: Outcome
Section 1: Demographic & Consultant


Primary identifier,
essential for data linkage
1010101013
{BLANK}
Secondary identifier, and
allows for analysis of
provision by age
2000-01-07
{BLANK}
Data Item
Commentary
NHS Number
Date of Birth
This is the format required, as
detailed in the SACT Data Set User
Guidance.
1
3
Gender – Current
To allow analysis by Gender
Ethnicity
To allow analysis by ONS
categories
Patient Postcode
To allow analysis of
HA1 1AA
{BLANK}
geographical patterns of
care
If your extract does not include data on a
C
Q
mandatory field, the record will be produce an
error message at the point of validation.
Section 1: Demographic & Consultant (2)
Data Item
Registered GP
Practice Code
In many cases theDemographic &

Consultant data items can be imported into
to report SACT from
the
This allows reporting of the system used
X00008
X123456789
hospital PAS interface
commissioning
Commentary
Consultant GMC
Code
This allows identification of
consultant team and
patterns of management
D1234567
X1234567
Consultant
Speciality Code
This allows analysis by
speciality
146
X01
Organisational
Code of Provider
This is the code of the
provider initiating the
programme of
chemotherapy
SPH00
{BLANK}
If you report the Trust 3-digit code, all
your reports will be produced at a Trustlevel.
Section 2: Clinical Status
Data Item
Commentary
Primary Diagnosis
ICD10: to allow analysis
by tumour site
Morphology
ICD03: is essential for
some tumour sites e.g.
Haematology & Lung
where ICD10 is
inadequate
Stage of Disease
To allow analysis by stage,
which is essential for
outcome analysis


C348
{BLANK}
For SACT, this is the PRIMARY DIAGNOSIS at
the start of the Systemic Anti-Cancer
Therapy. 82633
{BLANK}
This is the PATIENT DIAGNOSIS for the cell
type of the malignant disease recorded as
part of a Cancer Care Spell.
421
000
Section 3: Programme & Regimen
Data Item
Commentary


Programme ID
To allow for sequential
analysis of patient care,
may start at any number to
accommodate previous
treatment and is unique to
each patient.
03
00
Regimen Number
The national codes
•A Adjuvant (post-operative treatment)
To allow for sequential
02
00
•N Neo-adjuvant (therapy before
a main treatment)
analysis of patient care,
•C Curative (therapy intended to cure condition)
may start at any number to
Palliative (therapy intended to mitigate symptoms)
accommodate•Pprevious
treatment and•D
is Disease
unique Modification
to
each patient. (anticipated clinical improvement of at least a years duration)
Intent of Treatment
To allow analysis by
treatment intent
C
X
Section 3: Programme & Regimen (2)
Data Item
Commentary
Regimen
To be consistent with the
National Regimen List


GEMCARBO Days 1+8
{BLANK}
The National Regimen List (OPCS 4.6) is available
for download from the TRUD website.
Hospitals are expected to map local/network
regimen names to OPCS 4.6 for the purposes of
Payment by Results, which came into affect on 1st
April 2012.
The regimen name reported to SACT should be the
‘Dataset Short Version’, which is 35 characters.
Where a regimen cannot be mapped, as it is
waiting to be added to the list please send your
local/network regimen name.
Section 3: Programme & Regimen (3)


To allow comparison of
dose by metre2
1.66
0.00
Weight at Start of
Regimen
To allow comparison of
dose by metre2
81.5
0.00
Performance Status
at Start of Regimen
WHO or Lansky – to allow
case mix adjusted analysis
2
101
Co-morbidity
adjustment
Yes/No - to allow case mix
adjusted analysis
Date decision to
Treat
To allow analysis of wait
before treatment start
2011-05-01
1 May 2011
Start Date of
Regimen
To allow analysis by time
period
2011-05-10
{BLANK}
Data Item
Commentary
Height at Start of
Regimen
0 in both the
Y WHO and Lansky is
Xa
valid value – please check that your
system is not defaulting to ‘0’
Section 3: Programme & Regimen (4)
Data Item
Commentary


Clinical Trial
Yes/No – to identify
chemotherapy given within
clinical trials
N
X
Chemo-Radiation
Yes/No – to identify use of
chemo-radiation, only used
in recognised treatment
regimen
Y
X
Number of Planned
Cycles
To allow comparison with
number of cycles actually
given. Not necessary
relevant for palliative
treatment
4
0
Section 4: Cycle
Data Item
Commentary
Cycle Number
Sequential within each
regimen and indicates the
patients progress through
the regimen.
Start Date of Cycle
The date of the first
administration in each
cycle.
Weight at Start of
Cycle
Where relevant to allow for
dose reduction.
Performance Status
at Start of Cycle
To assess patient’s
suitability for further
treatment.
OPCS Procurement
Code


6
XX
2012-01-01
01 Jan 2012
81.5
0.00
2
101
X719
XXXX
Section 4: Cycle (2)
Data Item
OPCS Procurement
Code
Commentary


X711
XXXX
Section 5: Drug Details
Data Item
Commentary
Drug Name
This is the approved name
in the BNF, it identifies
individual drug usage
OPCS Delivery
Code


Gemcitabine
X
X722
X000
Section 5: Drug Details (2)
Data Item
Commentary


Actual Dose Per
Administration
For oral regimens this is the
daily dose. Allows
calculation of cumulative
dose per patient and global
drug usage.
120
XXX
Administration
Route
To allow analysis by route
of administration
04
22
Administration Date
The date of actual
administration.
2012-01-01
1 Jan 2012
Organisational
Code of Provider
This may change
throughout the regimen. To
Allow analysis by provider.
SPH00
XX999
Two common issues with date fields:
•3000+ records with a date out of
sequence i.e. Administration Date is before
Regimen Start Date
•Default date 01/01/1900 being reported
Section 6: Outcome


2012-01-01
1 Jan 2012
Yes/No – Where a dose of
any SACT drug is reduced
at any cycle
N
X
Regimen
Modification – Time
Delay
Yes/No – Where
administration of drugs is
delayed > 5 days at any
cycle
N
X
Regimen
Modification –
Stopped Early
Yes/No – Where the
regimen is abandoned
before the planned number
of cycles
Regimen Outcome
Summary
To record the immediate
outcome of the treatment
Date of Death
To estimate 30-day
mortality
Data Item
Commentary
Date of Final Cycle
Date of Start of Final
Treatment
Regimen
Modification – Dose
Reduction
As the Chemotherapy Intelligence Unit is
hosted within a Cancer Registry they will
N of Death details as part
X of the
receive Date
Office of National Statistics ‘Cancer Deaths’
and ‘Non Cancer Deaths’ which they will
use to append to the patient record.
Progressive disease
during chemotherapy
X
2012-02-01
1 Feb 2012
SACT Dataset User Guidance
The SACT Dataset Implementation User Guidance contains detailed
information on data format and content.
The Guide can be accessed as a downloadable pdf:
- on the SACT / ISB websites
www.isb.nhs.uk
www.chemodataset.nhs.uk
FAQ of common problems encountered are also available.
www.chemodataset.nhs.uk/frequently_asked_questions/
ciu
Chemotherapy Intelligence Unit
3. Regimen Mapping
Regimen mapping and how it applies
within SACT
Chemotherapy Intelligence Unit
4150 Chancellor Court
Oxford Business Park South
Oxford
OX4 2GX
Email: [email protected]
Website: www.chemodataset.nhs.uk
What is Regimen Mapping?
A regimen is a regulated course of medical treatment that
consists of one or more drugs administered over a period
of time. It may consist of several cycles of treatment, each
featuring numerous separate drug administrations.
Local clinicians may use different names to refer to the
same course of treatment. Regimen mapping standardises
data within the dataset by linking local names to a central
regimens list without changing local practice.
SACT Regimen Mapping
• Local regimen names need to be mapped against DH
Chemotherapy Regimens List.
• Trusts do not need to change local names.
• Cancer pharmacists are key to this.
• If we receive an non-mapped regimen name then this
will appear on the SACT Online mapping tool.
• This will then allow you to map your local name to the
national list or the component BNF drug name.
• Once a local regimen is mapped it will be applied to your
organisations mapping tables and it will not need to be
mapped again.
Regimen name submission
New unmapped regimens
appear in red. They can be
mapped to existing regimens
or proposed as new regimens
via the SACT website.
There is no requirement to change
nomenclature at trust level, but
there is a need to be able to map to
recognisable groupings / regimen names
if the CIU are to be able to compare
regimens for effective analysis
OPCS 4.7
Regimen Name
(Dataset short version)
Bevacizumab+temoz+RT
(weeks 1 to 6)
Bevacizumab+temoz+RT
(weeks 1 to 6)
Bevacizumab+temoz+RT(we
eks7 to 9)
Bevacizumab+temoz+RT(we
eks7 to 9)
Bexarotene
BGEM
BGEM
BGEM
BGEM
BIP
BIP
BIP
Regimen name (Long version)
Bevacizumab + Temozolomide +RT weeks 1
to 6 (Glioblastoma new)
Bevacizumab + Temozolomide +RT weeks 1
to 6 (Glioblastoma new)
Bevacizumab + Temozolomide +RT weeks 7
to 9 (Glioblastoma new)
Bevacizumab + Temozolomide +RT weeks 7
to 9 (Glioblastoma new)
Bexarotene
BGEM
BGEM
BGEM
BGEM
BIP
BIP
BIP
Component
Drug name
Bevacizumab
Temozolomide
Bevacizumab
Temozolomide
Bexarotene
Carmustine
Etoposide
Gemcitabine
Melphalan
Bleomycin
Cisplatin
Ifosfamide
Find out more about
Regimen Mapping
The NHS OPCS-4
Chemotherapy
Regimens List can
be downloaded from
the HSCIC/TRUD
website. You will
need to register and
create an account in
order to do this.
https://isd.hscic.gov.uk
ciu
Chemotherapy Intelligence Unit
4. The SACT website & portal
Resources and functionality
Chemotherapy Intelligence Unit
4150 Chancellor Court
Oxford Business Park South
Oxford
OX4 2GX
Email: [email protected]
Website: www.chemodataset.nhs.uk
https://www.chemodataset.nhs.uk/home.aspx
Notes:
•You have to be a registered
user to access the SACT Portal;
•When registering you will be
asked what permission you
require:
•Upload Data
•Provider Approver; or
•Network
•You can only access the Portal
via the NHS N3!
Only users with ‘Upload Data’ permission will see
information in this box. If this is your first month of
submission, there will be ‘no files are waiting for
submission’
The CIU Helpdesk will
update this section each
month with relevant
information.
The CIU team has developed a
video that will talk you through
how to upload your SACT file to
the Upload Portal.
You have the ability to filter on
the file status.
Note: You will need Adobe
Flash Player to run the video
Select Organisation
You can also access the video on
how to upload your monthly
SACT file here.
Once your monthly file is validated
it will display a report on the
quality of the data contained in
your extract
Most entries will be
partially rather than fully
valid. Fully valid means all
fields are completed,
including Date of Death.
The minimum threshold is 80% of
mandatory fields must be partially valid.
Aim for 100%.
1. Submit button will not be
available until you meet 80%
minimum threshold;
2. Remember to submit between
1st and 15th of each month!
1. SACT data awaiting provider approval
is available from 16th to end of month.
2. You must be registered with provider
approval to view
In order to get Patient Count you
must submit:
•Admin Date
•Drug Name
In order to get Cycle Starts you
must submit
•Cycle Start Date
This is the ‘provider approvers’
opportunity to provide
commentary on the current
month’s activity. These notes
will be viewed by the analysis
team at the CIU.
ciu
Chemotherapy Intelligence Unit
5. Quality Assurance
Data reporting and QA process
Chemotherapy Intelligence Unit
4150 Chancellor Court
Oxford Business Park South
Oxford
OX4 2GX
Email: [email protected]
Website: www.chemodataset.nhs.uk
Monitoring SACT Conformance
All Trusts are monitored for correct
submission and approval of SACT data.
An 80% minimum quality threshold is in force;
although trusts are encouraged to aim for
100%.
A monthly SACT Data Completeness report
detailing progress is sent to all Trusts.
mandatoryprovider
mandatory
provider approval
approval
correct
correct regimen
regimen grouping
grouping
regimen
regimen profile
profile confirm
confirm
outlier
outlier scrutiny
scrutiny
process review and
update (continuous)
data quality analysis
process review and update
(continuous)
SACT data and reporting
quality assurance processes
SACT data and quality assurance processes
concentrate on five areas.
data
quality
analysis
mandatory
provider
approval
correct
regimen
grouping
regimen
profile
confirm
outlier
scrutiny
process review and update (continuous)
1. Data Quality Analysis
data
quality
analysis
mandatory
provider
approval
correct
regimen
grouping
regimen
profile
confirm
outlier
scrutiny
process review and update (continuous)
2. Mandatory Provider
Approval
data quality
analysis
mandatory
provider
approval
correct
regimen
grouping
regimen
profile
confirm
outlier
scrutiny
process review and update (continuous)
3. Correct Regimen Grouping
• Wide variation in regimen naming
• In excess of 20,000 different regimen
names submitted
• Some intelligible others unintelligible
– Dr No’s regimen
– Breast regimen #5
• Need common nomenclature for analysis
• DH Chemotherapy Regimens List (OPCS
4.6)1
• Mapped manually to 2,000 comparable
regimens
1. Available at
https://www.uktcregistration.nss.cfh.nhs.uk/trud3/user/guest/group/0/home
data
quality
analysis
mandatory
provider
approval
correct
regimen
grouping
regimen
profile
confirm
outlier
scrutiny
process review and update (continuous)
3. Correct Regimen Grouping
data
quality
analysis
mandatory
provider
approval
correct
regimen
grouping
regimen
profile
confirm
outlier
scrutiny
process review and update (continuous)
4. Regimen Profile Confirmation
Lower GI
All submitting trusts aggregated
Example: English NHS hospital trust
2,164
CAPECEITABINE + OXALIPLATIN
1,544
OXALIPLATIN + MDG
552
1,550
4,726
757
IRINOTECAN + MDG
4,181
BEVACIZUMAB
340
CETUXIMAB
240
BEVACIZUMAB + IRINOTECAN + MDG
176
SCOT TRIAL
214
CAPECITABINE + IRINOTECAN
184
2,058
1,818
1,194
1,020
840
0
2,000
4,000
6,000
Number of cycles
87
839
221
CAPECITABINE
5,043
CAPECITABINE
1,062
FLUOROURACIL
8,987
FLUOROURACIL
209
CAPECEITABINE + OXALIPLATIN
9,014
8,000
10,000
606
OXALIPLATIN + MDG
48
IRINOTECAN
57
253
229
CAPECITABINE + IRINOTECAN
32
BEVACIZUMAB
25
CETUXIMAB + IRINOTECAN
14
152
130
108
IRINOTECAN + MDG
13
46
CETUXIMAB
10
45
0
200
400
600
800
Number of cycles
1,000
1,200
data
quality
analysis
mandatory
provider
approval
correct
regimen
grouping
regimen
profile
confirm
outlier
scrutiny
process review and update (continuous)
5. Outlier Scrutiny
1.
2.
3.
4.
Screen analyses for unusual patterns of activity.
Re-analyse to confirm outlier finding.
Seek expert opinion on current practice.
Decide if this an issue that is:
a) In acceptable range but limited patient
choice.
b) Acceptable practice but worrying trend.
c) Of potential clinical concern.
5. If c, write formally to trust medical director and
clinical cancer lead informing them of the finding
and giving them 28 days to respond.
6. In all cases continue to monitor and review
practice.
data quality
analysis
mandatory
provider
approval
correct
regimen
grouping
regimen
profile
confirm
outlier
scrutiny
process review and update (continuous)
SACT data and reporting quality
assurance processes
“ensuring variations in clinical practice
are represented accurately in the new
national cancer chemotherapy (SACT)
programme”
ciu
Chemotherapy Intelligence Unit
6. SACT Data Analysis
Analysis and reporting
Chemotherapy Intelligence Unit
4150 Chancellor Court
Oxford Business Park South
Oxford
OX4 2GX
Email: [email protected]
Website: www.chemodataset.nhs.uk
DC & DQ (6 month reviews)
 The first SACT Data Quality and Data Completeness review packs,
part of our data quality and data completeness strategy are being
sent out.
 The packs include (Trust specific)
• DC Profile & DQ profile
• Volume charts, by cycle start date, by unique patient count
• Demographics profile
• SACT Questionnaire
 The goals of this strategy are to increase:
• SACT data – Engagement – Information for further strategies.
• Improve quality at trust level, enhancing the value of their own
reports as well as the value of the SACT dataset.
SACT Analysis What to Expect...
Once sufficient data have been quality assured and analysed,
reports are issued to contributing providers. This is a continuing
process and requires careful governance and maintenance.
Benefits
Valuable for those providing and commissioning chemotherapy
services.
It will support patients and their clinical teams in choosing
appropriate care, based on accurate knowledge of current practice
and the corresponding benefits and toxicities of treatment.
Analysis sequence - monthly
“Sense check” completed by next submission
April
1st
Monthly submissions >>>>>>
Diagnostic
group
Each trust receives
feedback on the
technical quality of
individual and global
data monthly (by return).
Regimen
starts
Cycle
starts
Breast
30
200
Lower GI
25
180
Gynae
25
60
Lung
16
80
Lymphoma
28
230
Urology
12
56
etc
Monthly Snapshot –
cumulative figures
September ‘13 to
August ‘14
October ‘13 to
September ‘14
Patients Receiving Drug
Treatments
156,113
158,094
Regimens Commenced
256,712
262,166
Cycles Commenced
694,530
711,447
The figures listed above represent the number of patients reported to the
CIU through SACT, for whom treatment activity has been submitted for
the period covering October 2013 through September 2014 inclusive.
10,000
October
November
December
January
February
March
April
2013
May
Date of activity
2014
Source: SACT dataset; retrieved 5th November 2014
June
July
August
Regimens 13,697
Regimens 15,785
Regimens 19,041
Regimens 18,278
Cycles 52,234
Cycles 58,217
Cycles 65,220
Cycles 60,099
Cycles 60,041
Cycles 61,440
Cycles 56,928
Cycles 50,954
Cycles 56,114
Cycles 49,303
60,000
Regimens 18,512
Regimens 19,157
Regimens 19,557
Regimens 18,658
Regimens 20,741
Regimens 16,124
40,000
Cycles 49,716
Cycles 53,354
50,000
Regimens 17,826
Regimens 19,246
Number of records
Regimens and cycles month by month
Total number of regimens and cycles starting by month of activity
70,000
30,000
20,000
0
September
Data Quality and Completeness
Profiles for each Trust
All providers have
the ability to
download a data
quality and a data
completeness
profile that is
specific to their
trust and is
updated monthly.
Available for download at
www.chemodataset.nhs.uk
National Data Completeness for past
12 months
SACT Data Completeness report (October 2013 to September 2014)
England
All Diagnostic Groups
Number of
patients
Providers can
compare their
own data
completeness
to national
standards.
158,094 
Number of
tumour records
170,642 
Number of
regimens
262,166 
% NHS Number
100%
M
% GP Practice
Code
85%

% Programme
number
71%

% Comorbidity
adjustment
42%
Number of cycles
711,447 
Number of drug
records
1,858,864 
Number of
outcome records
173,353 
66% of regimens

% Cycle number
100%
M
% Drug name
100%

% Date of Final
Treatment
29%

% Date of Birth
100%
M
% GMC Code
91%

% Regimen
number
62%


% Start date of
cycle
95%

% Actual dose
per
administration
93%
99%

% Consultant
Specialty
92%

% Treatment
intent
% Date of
decision to treat
86%
% Current gender

80%

% Start date of
regimen
100%
M

94%

% Primary
diagnosis
100%

% Regimen name
100%
M
% Clinical trial
76%
57%

41%
100%


53%


22%

100%

% Regimen
modification
(stopped early)
42%

Source: SACT dataset; retrieved 5th Novembert 2014
% Stage of
disease at start
of programme
37%

% Performance
% Height at start % Weight at start
Status at start of
of regimen
of regimen
regimen

58%
% Chemo
radiation
65%

% OPCS
procurement
code
57%
64%


% Regimen
outcome
summary
7%
59%

40%

% Number of
cycles planned
% Administration % Administration % OPCS Delivery
route
date
code
94%
CIU will focus
data quality
efforts on fields
highlighted
M
% Morphology
% Performance
% Weight at start
Status at start of
of cycle
cycle
% Regimen
% Regimen
modification
modification (time
(dose reduction)
delay)
50%
% Patient
postcode
% Ethnicity
60%

% of Cycles with
Drug records
86%

% Organisation
code of drug
provider
96%

% Date of death

4%

Outcome
data
continues
to be low
and poses
a big
challenge
Data Completeness
by Trust
Providers can also compare their own
data completeness to that of other
trusts.
You will only appear on this report once
you have approved your monthly
submission;
Data Completeness by Tumour
Group for past 12 months
Completeness can also be
compared by tumour group.
Available for download at
www.chemodataset.nhs.uk
Analysis sequence – 3 monthly
Detailed individual and
global analysis reports are
produced three monthly
Individual trust
analysis – all
submitting
trusts
Global analysis
– all submitting
trusts
Top 10
regimens by
diagnostic group
– regimen and
cycle starts
% of total
patients by
diagnostic
group
+
Top 10
regimens by
diagnostic group
– regimen and
cycle starts
% of total
patients by
diagnostic
group
Total patients by diagnostic group
Shows number of patients
treated in each diagnostic group
globally and per trust.
Once contributing
providers have
submitted and
approved 3
consecutive months
of SACT activity they
will receive both a
global view and a
trust view of
‘Patients treated by
diagnostic group’
Available for download at www.chemodataset.nhs.uk
Top regimens by diagnostic group
The ‘top 10 regimens by diagnostic
group’ will be available to contributing
providers who have submitted and
approved 3 consecutive months of SACT
activity. Reports show the totals for all
submitting trusts…
…or for individual trusts. Providers have
the opportunity to compare their Trust
view with that of the global perspective.
Reports for all diagnostic groups
Also for types of disease / treatment
Analysis sequence – 6 monthly
Reports comparing trusts are
produced six monthly
“Sense check”completed by next submission
April
1st
Monthly submissions >>>>>>
Comparative trust analysis –
compares regimens used to
treat each diagnostic group
in different trusts.
Regimen Benchmarking
Regimen Benchmarking
Breast (All)
ICD10: C50
XXX NHS Hospital Trust
Hospital Trusts – number of patients
Data received for July 2013 - June 2014. Patients aged 16 and over
Comparison of regimens used to
treat each diagnostic group in
different trusts. Unmapped
regimens are in grey.
Analysis sequence –
annual
Global analysis
– all submitting
trusts
April
1st
Individual trust
analysis – all
submitting
trusts
Comparative
trust analysis –
all submitting
trusts
Annual reports analyse age
profile and geographical
distribution of patients
+
Age profile of treated patients
+
Geographical mapping of activity
Post Chemotherapy Mortality Analysis
From 25th July 2014 all NHS providers of Chemotherapy in England have
been able to access their post chemotherapy mortality analysis for 30, 60 and
90 days through the secure online portal.
This analysis is available by tumour group and provides a national
comparison.
It is essential that clinical teams within provider organisations check the
accuracy of their data and contact the team in Oxford where there are any
possible discrepancies.
A letter to Medical Directors and Lead Chemotherapy Consultants has been
sent out raising awareness of these reports.
Post Chemotherapy Mortality Analysis
(2)
For demonstration purposes only
Post Chemotherapy Mortality Analysis
(3)
For demonstration purposes only
Access these reports…
The website is updated
regularly; you can…
• download all England
analysis and data
completeness reports;
• and interactive regimen
analysis.
https://www.chemodataset.nhs.uk/home.aspx
ciu
Chemotherapy Intelligence Unit
7. Conclusion
Lessons learned and
future potential
Chemotherapy Intelligence Unit
4150 Chancellor Court
Oxford Business Park South
Oxford
OX4 2GX
Email: [email protected]
Website: www.chemodataset.nhs.uk
So… what lessons have we
learned?
-
Working closely with the
Commissioners of
Chemotherapy
-
-
NHS England Chemo contract;
Helpdesk (phone/email)
Support
-
Training/Data Liaison for each
provider
-
Access to Pharmacist support
in understanding regimen
nomenclature;
-
Establishing a well defined
information standard;
• Clinical engagement is vital
• Inc. CCIG
• Clinical data interrogation
workshops
• User Group is invaluable
• Engagement with software
suppliers (Varian, Elekta, CIS
Chemocare)
• Constant communication
• Newsletters
• Website
• Best practice
The potential of the SACT
Dataset
Effective comparison of treatments and corresponding
outcomes – what works?
Analysis:
• More detailed/more complex reports, for example top regimens by
diagnostic groups
• Dosage distribution
• Age distribution
• Mortality
• Establishing a base for more effective commissioning
• Ensuring that what is delivered is paid for by commissioners
We want to identify more best practice
across England and share it!
• We have already received a number of excellent
examples, which we will share via the SACT website.
• Have You:
• Improved SACT data quality by introducing new
processes?
• Used your local SACT data to improve services, or your
understanding of chemotherapy?
• Shared all SACT reports (Data Quality, Top Regimen,
Benchmarking and the mortality reports) with your
pharmacy and oncology teams members in order to
improve understanding SACT and its purpose?
• If yes, please contact us at [email protected]!
ciu
Chemotherapy Intelligence Unit
Find out more…
www.chemodataset.nhs.uk
Contact us…
[email protected]
Chemotherapy Intelligence Unit
4150 Chancellor Court
Oxford Business Park South
Oxford
OX4 2GX
Email: [email protected]
Website: www.chemodataset.nhs.uk
Helpdesk
01865 33 4740
01865 33 4781